Compass at Keystone’s Cancer Immunotherapy Symposium (March 24-28) in Keystone, Colorado

Compass at Keystone’s Cancer Immunotherapy Symposium (March 24-28) in Keystone, Colorado

Mar. 24, 2019 by

Meet Compass at the Keystone Innate and Non-Classical Immune Cells in Cancer Immunotherapy Symposium (March 24-28) in Keystone, Colorado, and learn about our a novel class of NK-Cell Engagers:  

Compass at the Cowen & Co. 39th Annual Health Care Conference 2019

Compass at the Cowen & Co. 39th Annual Health Care Conference 2019

Mar. 12, 2019 by

Meet Compass at the Cowen & Co. 39th Annual Health Care Conference 2019 (March 11-13) in Boston, Massachusetts.   March 12, 2019 at Boston Marriott Copley Place Presenter: Thomas Schuetz, M.D., Ph.D., Co-Founder

Compass Therapeutics to Present at J.P. Morgan Healthcare Conference

Compass Therapeutics to Present at J.P. Morgan Healthcare Conference

Jan. 3, 2019 by

CAMBRIDGE, Mass., January 3, 2019 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, will discuss its novel approach to antibody

Compass Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

Compass Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

Nov. 26, 2018 by

CAMBRIDGE, Mass., Nov. 26, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that Thomas Schuetz, M.D., Ph.D.,

Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

Nov. 6, 2018 by

CAMBRIDGE, Mass., Nov. 6, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that preclinical data on CTX-471,

FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company

FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company

Oct. 2, 2018 by

CAMBRIDGE, Mass., Oct 2, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that it has been named

Compass Therapeutics Completes $132 Million Series A Financing to Advance Next-Generation Antibody-Based Therapeutics into the Clinic

Compass Therapeutics Completes $132 Million Series A Financing to Advance Next-Generation Antibody-Based Therapeutics into the Clinic

Jul. 12, 2018 by

This is the excerpt for your very first post.